183 related articles for article (PubMed ID: 35895102)
1. Comparison of originator and biosimilar monoclonal antibodies using HRMS, Fc affinity chromatography, and 2D-HPLC.
Reinders LMH; Klassen MD; Teutenberg T; Jaeger M; Schmidt TC
Anal Bioanal Chem; 2022 Sep; 414(23):6761-6769. PubMed ID: 35895102
[TBL] [Abstract][Full Text] [Related]
2. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab.
Visser J; Feuerstein I; Stangler T; Schmiederer T; Fritsch C; Schiestl M
BioDrugs; 2013 Oct; 27(5):495-507. PubMed ID: 23649935
[TBL] [Abstract][Full Text] [Related]
3. Comparison of originator and biosimilar therapeutic monoclonal antibodies using comprehensive two-dimensional liquid chromatography coupled with time-of-flight mass spectrometry.
Sorensen M; Harmes DC; Stoll DR; Staples GO; Fekete S; Guillarme D; Beck A
MAbs; 2016 Oct; 8(7):1224-1234. PubMed ID: 27362833
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous Monitoring of Monoclonal Antibody Variants by Strong Cation-Exchange Chromatography Hyphenated to Mass Spectrometry to Assess Quality Attributes of Rituximab-Based Biotherapeutics.
Di Marco F; Berger T; Esser-Skala W; Rapp E; Regl C; Huber CG
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445776
[TBL] [Abstract][Full Text] [Related]
5. Hydrophilic Interaction Chromatography Hyphenated with Mass Spectrometry: A Powerful Analytical Tool for the Comparison of Originator and Biosimilar Therapeutic Monoclonal Antibodies at the Middle-up Level of Analysis.
D'Atri V; Fekete S; Beck A; Lauber M; Guillarme D
Anal Chem; 2017 Feb; 89(3):2086-2092. PubMed ID: 28208257
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Structural and Functional Comparability of Biosimilar Products: Trastuzumab as a Case Study.
Joshi S; Rathore AS
BioDrugs; 2020 Apr; 34(2):209-223. PubMed ID: 31975160
[TBL] [Abstract][Full Text] [Related]
7. Glycosylation of biosimilars: Recent advances in analytical characterization and clinical implications.
Duivelshof BL; Jiskoot W; Beck A; Veuthey JL; Guillarme D; D'Atri V
Anal Chim Acta; 2019 Dec; 1089():1-18. PubMed ID: 31627805
[TBL] [Abstract][Full Text] [Related]
8. Discovery and characterization of antibody variants using mass spectrometry-based comparative analysis for biosimilar candidates of monoclonal antibody drugs.
Li W; Yang B; Zhou D; Xu J; Ke Z; Suen WC
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jul; 1025():57-67. PubMed ID: 27214604
[TBL] [Abstract][Full Text] [Related]
9. Demonstrating Analytical Similarity of Trastuzumab Biosimilar HLX02 to Herceptin
Xie L; Zhang E; Xu Y; Gao W; Wang L; Xie MH; Qin P; Lu L; Li S; Shen P; Jiang W; Liu S
BioDrugs; 2020 Jun; 34(3):363-379. PubMed ID: 32072477
[TBL] [Abstract][Full Text] [Related]
10. Assessment of biosimilarity under native and heat-stressed conditions: rituximab, bevacizumab, and trastuzumab originators and biosimilars.
Kang J; Halseth T; Vallejo D; Najafabadi ZI; Sen KI; Ford M; Ruotolo BT; Schwendeman A
Anal Bioanal Chem; 2020 Jan; 412(3):763-775. PubMed ID: 31853605
[TBL] [Abstract][Full Text] [Related]
11. The criticality of high-resolution N-linked carbohydrate assays and detailed characterization of antibody effector function in the context of biosimilar development.
Brady LJ; Velayudhan J; Visone DB; Daugherty KC; Bartron JL; Coon M; Cornwall C; Hinckley PJ; Connell-Crowley L
MAbs; 2015; 7(3):562-70. PubMed ID: 25898160
[TBL] [Abstract][Full Text] [Related]
12. Comparison of glycoprofiles of rituximab versions licensed for sale in India and an analytical approach for quality assessment.
Kaur T; Shukla BN; Yadav VK; Kulkarni MJ; Rao A
J Proteomics; 2021 Jul; 244():104267. PubMed ID: 34015520
[TBL] [Abstract][Full Text] [Related]
13. Cutting-edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies.
Beck A; Debaene F; Diemer H; Wagner-Rousset E; Colas O; Van Dorsselaer A; Cianférani S
J Mass Spectrom; 2015 Feb; 50(2):285-97. PubMed ID: 25800010
[TBL] [Abstract][Full Text] [Related]
14. An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin.
Gianoncelli A; Bonini SA; Bertuzzi M; Guarienti M; Vezzoli S; Kumar R; Delbarba A; Mastinu A; Sigala S; Spano P; Pani L; Pecorelli S; Memo M
BioDrugs; 2015 Aug; 29(4):285-300. PubMed ID: 26334631
[TBL] [Abstract][Full Text] [Related]
15. Physicochemical and Biological Characterization of RTXM83, a New Rituximab Biosimilar.
Cerutti ML; Pesce A; Bès C; Seigelchifer M
BioDrugs; 2019 Jun; 33(3):307-319. PubMed ID: 30927214
[TBL] [Abstract][Full Text] [Related]
16. Analytical comparability study of anti-CD20 monoclonal antibodies rituximab and obinutuzumab using a stability-indicating orthogonal testing protocol: Effect of structural optimization and glycoengineering.
Trabik YA; Moenes EM; Al-Ghobashy MA; Nebsen M; Ayad MF
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Nov; 1159():122359. PubMed ID: 32920338
[TBL] [Abstract][Full Text] [Related]
17. Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin's Lymphoma: A Systematic Review and Meta-analysis.
Lee S; Lee H; Kim E
BioDrugs; 2019 Oct; 33(5):469-483. PubMed ID: 31446557
[TBL] [Abstract][Full Text] [Related]
18. How Similar Is Biosimilar? A Comparison of Infliximab Therapeutics in Regard to Charge Variant Profile and Antigen Binding Affinity.
Beyer B; Walch N; Jungbauer A; Lingg N
Biotechnol J; 2019 Apr; 14(4):e1800340. PubMed ID: 30315690
[TBL] [Abstract][Full Text] [Related]
19. Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLe study (Mixed cryoglobulinemiA Rituximab BiosimiLar).
Vacchi C; Visentini M; Gragnani L; Fraticelli P; Tavoni A; Filippini D; Saccardo F; Lauletta G; Colantuono S; Atzeni F; Pioltelli P; Manfredi A; Casato M; Zignego AL; Monti G; Pietrogrande M; Galli M; Sebastiani M
Intern Emerg Med; 2021 Jan; 16(1):149-156. PubMed ID: 32524338
[TBL] [Abstract][Full Text] [Related]
20. Severe Hypersensitivity Reactions at Biosimilar versus Originator Rituximab Treatment Initiation, Switch and Over Time: A Cohort Study on the French National Health Data System.
Jourdain H; Hoisnard L; Sbidian E; Zureik M
BioDrugs; 2023 May; 37(3):397-407. PubMed ID: 36877448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]